SMEs Are Keen Users Of EMA Regulatory Support, But Say They Want More
This article was originally published in SRA
Executive Summary
In the 10 years since the European Medicines Agency set up a dedicated office to offer advice to small and medium-sized companies in 2006, SMEs have filed 119 marketing authorization applications and have been assiduous users of the EMA's scientific advice process, especially for biomarker qualification and parallel advice with health technology assessment (HTA) bodies.
You may also be interested in...
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.
UK Explains New Rules On Parallel Imports From EU
Guidance from the Medicines and Healthcare products Regulatory Agency says that the packaging of parallel imported medicines must make clear that they are for the UK market only.